Skip to main content
  • Retraction Note
  • Open access
  • Published:

Retraction Note: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway

The Original Article was published on 22 November 2013

Retraction Note: Mol Cancer 12, 147 (2013)

https://doi.org/10.1186/1476-4598-12-147

The Editor in Chief has retracted this article because of significant concerns regarding a number of Figures presented in this work, which question the integrity of the data. There were found to be overlapping images in figure 3A between the Vandetanib and the Sunitinib and in figure 7A between the PC-3 α-santalol 10μM and the PC-3 α-santalol 20μM. Images in Figure 3C were found to overlap with images found in Figure 5 of a previously published article [1]. Images in Figure 5A were found to overlap with images found in Figure 4A of a previously published article [2]. Images in Figure 5E were found to overlap with images found in Figure 3D of a previously published article [3].

Sarita Saraswati has not responded to any correspondence from the editor/publisher about this retraction. The Publisher has not been able to obtain a current email address for authors Shakti Kumar and Abdulqader A Alhaider.

References

  1. Tang C, Shao X, Sun B, Huang W, Zhao X. The Effect of Self-Assembling Peptide RADA16-I on the Growth of Human Leukemia Cells in Vitro and in Nude Mice. Int J Mol Sci. 2009;10:2136–45. https://doi.org/10.3390/ijms10052136.

    Article  CAS  Google Scholar 

  2. Chang C-H, Li J-R, Shu K-H, Fu Y-C, Wu M-J. Hydronephrotic Urine in the Obstructed Kidney Promotes Urothelial Carcinoma Cell Proliferation, Migration, Invasion through the Activation of mTORC2-AKT and ERK Signaling Pathways. PLoS One. 2013;8(9):e74300. https://doi.org/10.1371/journal.pone.0074300.

    Article  CAS  Google Scholar 

  3. McConnell BV, Koto K, Gutierrez-Hartmann A. Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer. 2011;10:75. https://doi.org/10.1186/1476-4598-10-75.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sarita Saraswati.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saraswati, S., Kumar, S. & Alhaider, A.A. Retraction Note: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer 21, 223 (2022). https://doi.org/10.1186/s12943-022-01700-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12943-022-01700-y